The Dependency Map (DepMap) is a genome-wide pooled CRISPR-Cas9 knockout proliferation screen conducted in more than 700 cancer cell lines spanning many different tumor lineages. Each cell line in the DepMap contains a unique barcode, and each gene knockout is assigned a “dependency score” on a per cell-line basis which quantifies the rate of CRISPR-Cas9 guide drop. It has been found that proteins with similar DepMap scores across cell lines, a phenomenon known as co-dependent genes, have closely related biological functions. This can include activity in the same or parallel pathways or membership in the same protein complex or the same pathway.
We identified the strongest seven co-dependent genes (“Symbol”) for DUBs and ran GO enrichment analysis. We used Biogrid, IntAct, and Pathway Commons PPIDs, and the NURSA protein-protein interaction databases (PPIDs) to determine whether co-dependent genes interact with one another. The “Evidence” column contains the PPIDs in which the interaction appears as well as whether there is support for the association by an INDRA statement. As another approach to identify potential interactors, we looked at proteomics data from the Broad Institute's Cancer Cell Line Encyclopedia (CCLE) for proteins whose expression across ~375 cell lines strongly correlated with the abundance of each DUB; it has previously been observed that proteins in the same complex are frequently significantly co-expressed. The correlations and associated p-values in the CCLE proteomics dataset are provided. And, we determined whether co-dependent genes yield similar transcriptomic signatures in the Broad Institute's Connectivity Map (CMap). A CMap score greater than 90 is considered significantly similar.
Symbol | Name | DepMap Correlation | Evidence | CCLE Correlation | CCLE Z-score | CCLE p-value (adj) | CCLE Significant | CMAP Score | CMAP Type |
---|---|---|---|---|---|---|---|---|---|
TNIP1 | TNFAIP3 interacting protein 1 | 0.353 | BioGRID IntAct INDRA (22) Reactome (4) | 0.16 | 0.80 | 1.59e-02 | |||
NFKBIA | NFKB inhibitor alpha | 0.292 | INDRA (9) Reactome (8) | -0.05 | -0.38 | 5.63e-01 | 95.99 | oe | |
CYLD | CYLD lysine 63 deubiquitinase | 0.272 | INDRA (10) Reactome (15) | 0.14 | 0.66 | 7.05e-02 | |||
ATG101 | autophagy related 101 | 0.228 | -0.01 | -0.13 | 9.33e-01 | ||||
PPM1A | protein phosphatase, Mg2+/Mn2+ dependent 1A | 0.227 | Reactome (1) | -0.00 | -0.10 | 9.78e-01 | |||
IRAK1 | interleukin 1 receptor associated kinase 1 | -0.218 | INDRA (3) Reactome (6) | -0.00 | -0.10 | 9.78e-01 | -99.89 | kd | |
EPG5 | ectopic P-granules 5 autophagy tethering factor | 0.216 | 0.12 | 0.59 | 1.04e-01 |
Gene set enrichment analysis was done on the genes correlated with TNFAIP3using the terms from Gene Ontology and gene sets derived from the Gene Ontology Annotations database via MSigDB.
Using the biological processes and other Gene Ontology terms from well characterized DUBs as a positive control, several gene set enrichment analyses were considered. Threshold-less methods like GSEA had relatively poor results. Over-representation analysis with a threshold of of the top 7 highest absolute value Dependency Map correlations yielded the best results and is reported below.
The following table shows the significantly differentially expressed genes after knocking out TNFAIP3 using CRISPR-Cas9.
The GSEA method was applied for all genes whose knockout resulted in at least 20 significantly differentially expressed genes.
ID | Name | p-value | p-value (adj.) | log2 Error | ES | NES |
---|---|---|---|---|---|---|
msig:M5890 | HALLMARK_TNFA_SIGNALING_VIA_NFKB | 8.15e-14 | 3.19e-10 | 9.55e-01 | 6.01e-01 | 2.63e+00 |
go:0030545 | receptor regulator activity | 1.65e-11 | 3.22e-08 | 8.63e-01 | 6.23e-01 | 2.59e+00 |
msig:M9809 | KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 1.24e-09 | 1.61e-06 | 7.88e-01 | 6.85e-01 | 2.52e+00 |
go:0005126 | cytokine receptor binding | 6.93e-09 | 5.41e-06 | 7.61e-01 | 5.85e-01 | 2.40e+00 |
go:0031012 | extracellular matrix | 6.12e-09 | 5.41e-06 | 7.61e-01 | 5.30e-01 | 2.31e+00 |
go:0019221 | cytokine-mediated signaling pathway | 1.22e-08 | 7.94e-06 | 7.48e-01 | 3.79e-01 | 1.91e+00 |
go:0005125 | cytokine activity | 1.86e-08 | 1.04e-05 | 7.34e-01 | 7.45e-01 | 2.59e+00 |
go:0010469 | regulation of signaling receptor activity | 2.37e-08 | 1.16e-05 | 7.34e-01 | 5.08e-01 | 2.24e+00 |
msig:M5930 | HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 6.54e-08 | 2.84e-05 | 7.05e-01 | 5.41e-01 | 2.29e+00 |
go:0005102 | signaling receptor binding | 7.84e-08 | 3.06e-05 | 7.05e-01 | 3.24e-01 | 1.69e+00 |
go:0050900 | leukocyte migration | 1.69e-07 | 6.01e-05 | 6.90e-01 | 4.76e-01 | 2.13e+00 |
go:0034097 | response to cytokine | 1.85e-07 | 6.02e-05 | 6.90e-01 | 3.17e-01 | 1.67e+00 |
go:0009607 | response to biotic stimulus | 3.33e-07 | 9.31e-05 | 6.75e-01 | 3.54e-01 | 1.80e+00 |
go:0009617 | response to bacterium | 3.31e-07 | 9.31e-05 | 6.75e-01 | 4.46e-01 | 2.06e+00 |
go:0008083 | growth factor activity | 4.64e-07 | 1.21e-04 | 6.75e-01 | 6.70e-01 | 2.38e+00 |
go:0097530 | granulocyte migration | 5.64e-07 | 1.38e-04 | 6.59e-01 | 6.64e-01 | 2.32e+00 |
go:0062023 | collagen-containing extracellular matrix | 6.16e-07 | 1.42e-04 | 6.59e-01 | 5.16e-01 | 2.18e+00 |
go:0060326 | cell chemotaxis | 7.75e-07 | 1.68e-04 | 6.59e-01 | 5.37e-01 | 2.23e+00 |
go:0002237 | response to molecule of bacterial origin | 1.30e-06 | 2.68e-04 | 6.44e-01 | 4.86e-01 | 2.09e+00 |
go:0097529 | myeloid leukocyte migration | 1.89e-06 | 3.69e-04 | 6.44e-01 | 5.90e-01 | 2.26e+00 |
reactome:R-HSA-1280215 | Cytokine Signaling in Immune system | 2.53e-06 | 4.49e-04 | 6.27e-01 | 3.26e-01 | 1.68e+00 |
go:0006954 | inflammatory response | 2.46e-06 | 4.49e-04 | 6.27e-01 | 4.08e-01 | 1.92e+00 |
go:0005783 | endoplasmic reticulum | 4.34e-06 | 7.37e-04 | 6.11e-01 | 2.69e-01 | 1.49e+00 |
go:0030595 | leukocyte chemotaxis | 5.74e-06 | 9.34e-04 | 6.11e-01 | 5.52e-01 | 2.18e+00 |
go:1990266 | neutrophil migration | 6.30e-06 | 9.47e-04 | 6.11e-01 | 6.87e-01 | 2.30e+00 |
go:0001816 | cytokine production | 6.27e-06 | 9.47e-04 | 6.11e-01 | 3.54e-01 | 1.75e+00 |
go:0005201 | extracellular matrix structural constituent | 8.78e-06 | 1.27e-03 | 5.93e-01 | 7.15e-01 | 2.27e+00 |
reactome:R-HSA-449147 | Signaling by Interleukins | 9.91e-06 | 1.38e-03 | 5.93e-01 | 3.50e-01 | 1.73e+00 |
go:1990868 | response to chemokine | 1.41e-05 | 1.89e-03 | 5.93e-01 | 7.65e-01 | 2.26e+00 |
msig:M15569 | KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY | 1.62e-05 | 2.12e-03 | 5.76e-01 | 6.94e-01 | 2.30e+00 |
go:0071216 | cellular response to biotic stimulus | 2.29e-05 | 2.88e-03 | 5.76e-01 | 4.83e-01 | 1.99e+00 |
msig:M5913 | HALLMARK_INTERFERON_GAMMA_RESPONSE | 2.49e-05 | 3.01e-03 | 5.76e-01 | 4.64e-01 | 1.97e+00 |
go:0043062 | extracellular structure organization | 2.54e-05 | 3.01e-03 | 5.76e-01 | 4.27e-01 | 1.89e+00 |
msig:M5947 | HALLMARK_IL2_STAT5_SIGNALING | 3.12e-05 | 3.48e-03 | 5.57e-01 | 4.73e-01 | 1.98e+00 |
msig:M5932 | HALLMARK_INFLAMMATORY_RESPONSE | 3.07e-05 | 3.48e-03 | 5.57e-01 | 4.84e-01 | 1.98e+00 |
msig:M4844 | KEGG_CHEMOKINE_SIGNALING_PATHWAY | 3.71e-05 | 4.02e-03 | 5.57e-01 | 5.43e-01 | 2.09e+00 |
go:0071396 | cellular response to lipid | 4.19e-05 | 4.42e-03 | 5.57e-01 | 3.54e-01 | 1.73e+00 |
go:0048585 | negative regulation of response to stimulus | 4.44e-05 | 4.45e-03 | 5.57e-01 | 2.70e-01 | 1.46e+00 |
go:0006952 | defense response | 4.44e-05 | 4.45e-03 | 5.57e-01 | 2.83e-01 | 1.50e+00 |
go:0040017 | positive regulation of locomotion | 4.64e-05 | 4.54e-03 | 5.57e-01 | 3.45e-01 | 1.69e+00 |
go:1901701 | cellular response to oxygen-containing compound | 5.14e-05 | 4.78e-03 | 5.57e-01 | 2.95e-01 | 1.54e+00 |
go:0002684 | positive regulation of immune system process | 5.07e-05 | 4.78e-03 | 5.57e-01 | 3.07e-01 | 1.58e+00 |
msig:M12868 | KEGG_PATHWAYS_IN_CANCER | 7.14e-05 | 6.34e-03 | 5.38e-01 | 3.93e-01 | 1.78e+00 |
reactome:R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 7.00e-05 | 6.34e-03 | 5.38e-01 | 6.02e-01 | 2.10e+00 |
msig:M5925 | HALLMARK_E2F_TARGETS | 7.70e-05 | 6.64e-03 | 5.38e-01 | -3.75e-01 | -1.75e+00 |
go:0051240 | positive regulation of multicellular organismal process | 7.81e-05 | 6.64e-03 | 5.38e-01 | 2.70e-01 | 1.45e+00 |
go:0002224 | toll-like receptor signaling pathway | 8.09e-05 | 6.65e-03 | 5.38e-01 | 5.48e-01 | 2.08e+00 |
go:0032103 | positive regulation of response to external stimulus | 8.17e-05 | 6.65e-03 | 5.38e-01 | 4.64e-01 | 1.95e+00 |
go:0071548 | response to dexamethasone | 9.42e-05 | 7.51e-03 | 5.38e-01 | 7.29e-01 | 2.11e+00 |
go:0042127 | regulation of cell population proliferation | 9.86e-05 | 7.71e-03 | 5.38e-01 | 2.69e-01 | 1.44e+00 |
go:0006959 | humoral immune response | 1.16e-04 | 8.91e-03 | 5.38e-01 | 6.10e-01 | 2.11e+00 |
go:0046545 | development of primary female sexual characteristics | 1.19e-04 | 8.92e-03 | 5.38e-01 | 5.76e-01 | 2.05e+00 |
go:0050918 | positive chemotaxis | 1.56e-04 | 1.15e-02 | 5.19e-01 | 7.05e-01 | 2.09e+00 |
go:0050921 | positive regulation of chemotaxis | 1.86e-04 | 1.33e-02 | 5.19e-01 | 5.34e-01 | 1.99e+00 |
go:0097190 | apoptotic signaling pathway | 2.04e-04 | 1.42e-02 | 5.19e-01 | 3.02e-01 | 1.53e+00 |
reactome:R-HSA-375276 | Peptide ligand-binding receptors | 2.13e-04 | 1.46e-02 | 5.19e-01 | 6.95e-01 | 2.12e+00 |
reactome:R-HSA-373076 | Class A/1 (Rhodopsin-like receptors) | 2.43e-04 | 1.63e-02 | 5.19e-01 | 6.40e-01 | 2.12e+00 |
go:1903900 | regulation of viral life cycle | 2.47e-04 | 1.63e-02 | 4.98e-01 | 4.43e-01 | 1.87e+00 |
go:0023057 | negative regulation of signaling | 2.78e-04 | 1.75e-02 | 4.98e-01 | 2.71e-01 | 1.45e+00 |
go:0002682 | regulation of immune system process | 2.75e-04 | 1.75e-02 | 4.98e-01 | 2.64e-01 | 1.40e+00 |
go:0042330 | taxis | 2.71e-04 | 1.75e-02 | 4.98e-01 | 3.65e-01 | 1.70e+00 |
go:0071384 | cellular response to corticosteroid stimulus | 3.17e-04 | 1.97e-02 | 4.98e-01 | 5.86e-01 | 2.02e+00 |
go:0001775 | cell activation | 3.45e-04 | 2.07e-02 | 4.98e-01 | 2.67e-01 | 1.41e+00 |
go:0001664 | G protein-coupled receptor binding | 3.41e-04 | 2.07e-02 | 4.98e-01 | 5.01e-01 | 1.97e+00 |
go:0046660 | female sex differentiation | 3.71e-04 | 2.19e-02 | 4.98e-01 | 5.43e-01 | 2.01e+00 |
go:0048514 | blood vessel morphogenesis | 4.28e-04 | 2.46e-02 | 4.98e-01 | 3.38e-01 | 1.61e+00 |
go:0002690 | positive regulation of leukocyte chemotaxis | 4.84e-04 | 2.74e-02 | 4.98e-01 | 5.79e-01 | 2.01e+00 |
go:0035150 | regulation of tube size | 5.03e-04 | 2.80e-02 | 4.77e-01 | 5.93e-01 | 2.03e+00 |
go:0003682 | chromatin binding | 5.10e-04 | 2.80e-02 | 4.77e-01 | -3.17e-01 | -1.55e+00 |
go:1902533 | positive regulation of intracellular signal transduction | 5.19e-04 | 2.82e-02 | 4.77e-01 | 2.78e-01 | 1.43e+00 |
go:0001541 | ovarian follicle development | 5.29e-04 | 2.82e-02 | 4.77e-01 | 6.50e-01 | 2.04e+00 |
go:0032101 | regulation of response to external stimulus | 5.69e-04 | 2.92e-02 | 4.77e-01 | 3.24e-01 | 1.59e+00 |
go:0034121 | regulation of toll-like receptor signaling pathway | 5.63e-04 | 2.92e-02 | 4.77e-01 | 7.10e-01 | 2.01e+00 |
reactome:R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 5.88e-04 | 2.98e-02 | 4.77e-01 | 5.08e-01 | 1.94e+00 |
go:0003018 | vascular process in circulatory system | 6.15e-04 | 3.08e-02 | 4.77e-01 | 5.43e-01 | 1.90e+00 |
go:1903035 | negative regulation of response to wounding | 6.49e-04 | 3.21e-02 | 4.77e-01 | 6.12e-01 | 2.03e+00 |
go:0034612 | response to tumor necrosis factor | 6.70e-04 | 3.27e-02 | 4.77e-01 | 3.82e-01 | 1.72e+00 |
msig:M5921 | HALLMARK_COMPLEMENT | 6.92e-04 | 3.29e-02 | 4.77e-01 | 4.24e-01 | 1.79e+00 |
reactome:R-HSA-1474244 | Extracellular matrix organization | 6.99e-04 | 3.29e-02 | 4.77e-01 | 4.09e-01 | 1.73e+00 |
go:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 6.85e-04 | 3.29e-02 | 4.77e-01 | 4.79e-01 | 1.89e+00 |
go:0050819 | negative regulation of coagulation | 7.17e-04 | 3.34e-02 | 4.77e-01 | 6.81e-01 | 1.97e+00 |
go:2001234 | negative regulation of apoptotic signaling pathway | 7.30e-04 | 3.35e-02 | 4.77e-01 | 3.76e-01 | 1.68e+00 |
go:0005604 | basement membrane | 7.44e-04 | 3.38e-02 | 4.77e-01 | 6.17e-01 | 2.00e+00 |
msig:M19096 | KEGG_BLADDER_CANCER | 7.54e-04 | 3.38e-02 | 4.77e-01 | 6.17e-01 | 1.99e+00 |
go:0050778 | positive regulation of immune response | 7.82e-04 | 3.47e-02 | 4.77e-01 | 2.96e-01 | 1.49e+00 |
go:0055092 | sterol homeostasis | 7.91e-04 | 3.47e-02 | 4.77e-01 | 6.42e-01 | 2.01e+00 |
go:0035239 | tube morphogenesis | 8.38e-04 | 3.56e-02 | 4.77e-01 | 3.12e-01 | 1.56e+00 |
go:0097193 | intrinsic apoptotic signaling pathway | 8.26e-04 | 3.56e-02 | 4.77e-01 | 3.44e-01 | 1.60e+00 |
go:0043407 | negative regulation of MAP kinase activity | 8.39e-04 | 3.56e-02 | 4.77e-01 | 5.79e-01 | 1.98e+00 |
go:0060968 | regulation of gene silencing | 9.04e-04 | 3.72e-02 | 4.77e-01 | -4.21e-01 | -1.74e+00 |
go:0097191 | extrinsic apoptotic signaling pathway | 9.03e-04 | 3.72e-02 | 4.77e-01 | 3.83e-01 | 1.69e+00 |
go:0043408 | regulation of MAPK cascade | 9.35e-04 | 3.80e-02 | 4.77e-01 | 3.05e-01 | 1.52e+00 |
go:0040011 | locomotion | 9.90e-04 | 3.95e-02 | 4.55e-01 | 2.55e-01 | 1.37e+00 |
go:1901700 | response to oxygen-containing compound | 9.84e-04 | 3.95e-02 | 4.55e-01 | 2.48e-01 | 1.34e+00 |
go:0098780 | response to mitochondrial depolarisation | 1.04e-03 | 4.10e-02 | 4.55e-01 | -6.87e-01 | -1.92e+00 |
go:0006900 | vesicle budding from membrane | 1.08e-03 | 4.22e-02 | 4.55e-01 | 4.32e-01 | 1.76e+00 |
go:1901655 | cellular response to ketone | 1.09e-03 | 4.22e-02 | 4.55e-01 | 5.26e-01 | 1.90e+00 |
reactome:R-HSA-500792 | GPCR ligand binding | 1.11e-03 | 4.26e-02 | 4.55e-01 | 5.08e-01 | 1.88e+00 |
go:0002687 | positive regulation of leukocyte migration | 1.13e-03 | 4.29e-02 | 4.55e-01 | 4.98e-01 | 1.86e+00 |
go:0002685 | regulation of leukocyte migration | 1.18e-03 | 4.38e-02 | 4.55e-01 | 4.56e-01 | 1.80e+00 |
go:0002688 | regulation of leukocyte chemotaxis | 1.22e-03 | 4.50e-02 | 4.55e-01 | 5.34e-01 | 1.92e+00 |
go:0001819 | positive regulation of cytokine production | 1.25e-03 | 4.51e-02 | 4.55e-01 | 3.54e-01 | 1.60e+00 |
go:0000226 | microtubule cytoskeleton organization | 1.25e-03 | 4.51e-02 | 4.55e-01 | -2.99e-01 | -1.46e+00 |
go:0070373 | negative regulation of ERK1 and ERK2 cascade | 1.32e-03 | 4.75e-02 | 4.55e-01 | 5.29e-01 | 1.84e+00 |
go:0033993 | response to lipid | 1.34e-03 | 4.76e-02 | 4.55e-01 | 2.85e-01 | 1.45e+00 |
go:0044450 | 1.37e-03 | 4.83e-02 | 4.55e-01 | -4.02e-01 | -1.68e+00 | |
go:0046903 | secretion | 1.41e-03 | 4.92e-02 | 4.55e-01 | 2.46e-01 | 1.33e+00 |
go:0050684 | regulation of mRNA processing | 1.42e-03 | 4.92e-02 | 4.55e-01 | -3.81e-01 | -1.63e+00 |
go:0070972 | protein localization to endoplasmic reticulum | 1.50e-03 | 5.15e-02 | 4.55e-01 | 3.67e-01 | 1.64e+00 |
go:0002526 | acute inflammatory response | 1.56e-03 | 5.20e-02 | 4.55e-01 | 5.90e-01 | 1.95e+00 |
go:1903428 | positive regulation of reactive oxygen species biosynthetic process | 1.54e-03 | 5.20e-02 | 4.55e-01 | 6.58e-01 | 1.90e+00 |
go:0045087 | innate immune response | 1.55e-03 | 5.20e-02 | 4.55e-01 | 2.79e-01 | 1.42e+00 |
go:0034451 | centriolar satellite | 1.61e-03 | 5.32e-02 | 4.55e-01 | -6.75e-01 | -1.89e+00 |
go:0035295 | tube development | 1.66e-03 | 5.36e-02 | 4.55e-01 | 2.81e-01 | 1.43e+00 |
go:0010876 | lipid localization | 1.67e-03 | 5.36e-02 | 4.55e-01 | 3.70e-01 | 1.64e+00 |
go:0071622 | regulation of granulocyte chemotaxis | 1.67e-03 | 5.36e-02 | 4.55e-01 | 6.47e-01 | 1.92e+00 |
go:0023056 | positive regulation of signaling | 1.65e-03 | 5.36e-02 | 4.55e-01 | 2.44e-01 | 1.33e+00 |
go:0031401 | positive regulation of protein modification process | 1.80e-03 | 5.65e-02 | 4.55e-01 | 2.53e-01 | 1.33e+00 |
go:0031226 | intrinsic component of plasma membrane | 1.81e-03 | 5.65e-02 | 4.55e-01 | 2.83e-01 | 1.43e+00 |
go:0072599 | establishment of protein localization to endoplasmic reticulum | 1.88e-03 | 5.83e-02 | 4.55e-01 | 3.80e-01 | 1.65e+00 |
go:0050663 | cytokine production | 1.93e-03 | 5.94e-02 | 4.55e-01 | 4.70e-01 | 1.79e+00 |
go:0051247 | positive regulation of protein metabolic process | 1.95e-03 | 5.94e-02 | 4.55e-01 | 2.42e-01 | 1.32e+00 |
go:0005539 | glycosaminoglycan binding | 2.01e-03 | 6.05e-02 | 4.32e-01 | 4.55e-01 | 1.75e+00 |
go:0016050 | vesicle organization | 2.00e-03 | 6.05e-02 | 4.32e-01 | 3.29e-01 | 1.56e+00 |
msig:M5669 | KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 2.06e-03 | 6.15e-02 | 4.32e-01 | 5.10e-01 | 1.78e+00 |
go:2001236 | regulation of extrinsic apoptotic signaling pathway | 2.11e-03 | 6.16e-02 | 4.32e-01 | 4.13e-01 | 1.71e+00 |
go:1902883 | negative regulation of response to oxidative stress | 2.11e-03 | 6.16e-02 | 4.32e-01 | 5.77e-01 | 1.88e+00 |
go:0050920 | regulation of chemotaxis | 2.16e-03 | 6.25e-02 | 4.32e-01 | 4.45e-01 | 1.77e+00 |
go:2001233 | regulation of apoptotic signaling pathway | 2.19e-03 | 6.30e-02 | 4.32e-01 | 3.04e-01 | 1.48e+00 |
go:0002221 | pattern recognition receptor signaling pathway | 2.29e-03 | 6.45e-02 | 4.32e-01 | 4.32e-01 | 1.76e+00 |
go:0022602 | ovulation cycle process | 2.27e-03 | 6.45e-02 | 4.32e-01 | 6.63e-01 | 1.88e+00 |
go:1905954 | positive regulation of lipid localization | 2.30e-03 | 6.45e-02 | 4.32e-01 | 6.38e-01 | 1.90e+00 |
go:0070555 | response to interleukin-1 | 2.31e-03 | 6.45e-02 | 4.32e-01 | 3.81e-01 | 1.65e+00 |
go:0002253 | activation of immune response | 2.43e-03 | 6.72e-02 | 4.32e-01 | 3.05e-01 | 1.50e+00 |
go:1900117 | regulation of execution phase of apoptosis | 2.51e-03 | 6.91e-02 | 4.32e-01 | -6.19e-01 | -1.84e+00 |
go:2001242 | regulation of intrinsic apoptotic signaling pathway | 2.56e-03 | 6.98e-02 | 4.32e-01 | 3.73e-01 | 1.61e+00 |
reactome:R-HSA-1474290 | Collagen formation | 2.58e-03 | 6.99e-02 | 4.32e-01 | 5.62e-01 | 1.88e+00 |
go:0007186 | G protein-coupled receptor signaling pathway | 2.68e-03 | 7.21e-02 | 4.32e-01 | 3.32e-01 | 1.54e+00 |
msig:M5953 | HALLMARK_KRAS_SIGNALING_UP | 2.70e-03 | 7.22e-02 | 4.32e-01 | 4.40e-01 | 1.74e+00 |
go:0002274 | myeloid leukocyte activation | 2.86e-03 | 7.54e-02 | 4.32e-01 | 2.77e-01 | 1.40e+00 |
go:0002764 | immune response-regulating signaling pathway | 2.89e-03 | 7.57e-02 | 4.32e-01 | 3.00e-01 | 1.47e+00 |
go:0043409 | negative regulation of MAPK cascade | 3.07e-03 | 7.98e-02 | 4.32e-01 | 4.06e-01 | 1.66e+00 |
go:0035924 | cellular response to vascular endothelial growth factor stimulus | 3.14e-03 | 8.07e-02 | 4.32e-01 | 6.27e-01 | 1.86e+00 |
go:1903034 | regulation of response to wounding | 3.16e-03 | 8.07e-02 | 4.32e-01 | 4.67e-01 | 1.75e+00 |
go:0001764 | neuron migration | 3.13e-03 | 8.07e-02 | 4.32e-01 | -4.58e-01 | -1.72e+00 |
go:0061180 | mammary gland epithelium development | 3.27e-03 | 8.30e-02 | 4.32e-01 | 5.71e-01 | 1.85e+00 |
go:0032612 | interleukin-1 production | 3.49e-03 | 8.77e-02 | 4.32e-01 | 5.64e-01 | 1.87e+00 |
go:0001649 | osteoblast differentiation | 3.54e-03 | 8.77e-02 | 4.32e-01 | 3.97e-01 | 1.66e+00 |
go:0048194 | Golgi vesicle budding | 3.52e-03 | 8.77e-02 | 4.32e-01 | 4.25e-01 | 1.66e+00 |
go:0015918 | sterol transport | 3.54e-03 | 8.77e-02 | 4.32e-01 | 5.18e-01 | 1.79e+00 |
go:0050776 | regulation of immune response | 3.57e-03 | 8.77e-02 | 4.32e-01 | 2.69e-01 | 1.38e+00 |
go:0005814 | centriole | 3.63e-03 | 8.86e-02 | 4.32e-01 | -4.08e-01 | -1.64e+00 |
msig:M16848 | KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION | 3.69e-03 | 8.94e-02 | 4.32e-01 | 4.87e-01 | 1.73e+00 |
go:0008201 | heparin binding | 3.70e-03 | 8.94e-02 | 4.32e-01 | 4.85e-01 | 1.80e+00 |
go:0051094 | positive regulation of developmental process | 3.90e-03 | 9.34e-02 | 4.32e-01 | 2.55e-01 | 1.34e+00 |
go:0005788 | endoplasmic reticulum lumen | 3.95e-03 | 9.40e-02 | 4.07e-01 | 3.61e-01 | 1.59e+00 |
reactome:R-HSA-204005 | COPII-mediated vesicle transport | 4.08e-03 | 9.66e-02 | 4.07e-01 | 4.72e-01 | 1.76e+00 |
msig:M5948 | HALLMARK_BILE_ACID_METABOLISM | 4.12e-03 | 9.69e-02 | 4.07e-01 | 4.80e-01 | 1.70e+00 |
go:0032611 | interleukin-1 beta production | 4.16e-03 | 9.74e-02 | 4.07e-01 | 6.01e-01 | 1.86e+00 |
INDRA was used to automatically assemble known mechanisms related to TNFAIP3 from literature and knowledge bases. The first section shows only DUB activity and the second shows all other results.